Möchten Sie immer auf dem neuesten Stand bleiben?

TEL-AVIV, Israel, Jan. 9, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage,...

Upcoming milestones include: Top-line data from ongoing first Phase III study with RHB-105 for H. pylori infection expected Q2/2015 Top-line data from ongoing Phase III study with...

The UK MHRA has validated the European marketing application for the indications of chemotherapy and radiotherapy-induced nausea and vomiting; MHRA's feedback is expected during H2/2015...

The acquired diagnostic technology is intended for the detection of Mycobacterium avium subspecies paratuberculosis (MAP) bacterium; Increasing evidence supports the hypothesis that Crohn's...

The randomized, double-blind, placebo-controlled Phase III study with RHB-102 for acute gastroenteritis and gastritis (the GUARD study) is underway in the U.S., with a planned enrollment of 320...

RHB-102, newly branded as BEKINDA™, is a proprietary once-daily oral pill formulation of the antiemetic drug ondansetron The European marketing authorization application (MAA) seeks...

TEL-AVIV, Israel, Dec. 2, 2014 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company focused on late clinical-stage drugs for...

The German Federal Institute for Drugs and Medical Devices (BfArM) has validated the European Marketing Authorization Application submitted for RIZAPORT™ (RHB-103) and initiated its formal...

Under the FDA's Generating Antibiotic Incentives Now (GAIN) Act, the Qualified Infectious Disease Product (QIDP) designation allows for additional five years of market exclusivity in addition to...

A strong cash position of approximately $29 million at the end of the third quarter of 2014, enabling the Company to continue to execute its R&D programs including the three ongoing Phase III...